Robert A. Wolff

Robert A. Wolff's AcademicInfluence.com Rankings

Robert A. Wolff

Medical

#2470

World Rank

#2897

Historical Rank

Oncology

#151

World Rank

#157

Historical Rank

medical Degrees

Robert A. Wolff

Philosophy

#7185

World Rank

#10358

Historical Rank

Ontology

#77

World Rank

#87

Historical Rank

Logic

#4254

World Rank

#5524

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Robert A. Wolff Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert A. Wolff's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. (2007) (3726)
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer (2008) (1144)
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy (2006) (762)
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. (2008) (730)
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (725)
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. (2008) (699)
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. (2008) (631)
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. (2004) (566)
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. (2008) (551)
Pancreaticoduodenectomy with vascular resection: margin status and survival duration (2004) (545)
Pancreatic cancer (2004) (541)
Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma (2007) (538)
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID‐19) Pandemic: An International Collaborative Group (2020) (528)
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. (2004) (489)
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. (2010) (464)
Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma (2009) (449)
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators (2012) (444)
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. (2008) (444)
Pancreatic Adenocarcinoma, Version 1.2019. (2012) (415)
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications (2014) (336)
Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration (2001) (336)
Risk Factors for Pancreatic Cancer: Case-Control Study (2007) (317)
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (2021) (309)
Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer (2007) (307)
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. (2012) (303)
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. (2017) (287)
Improved Overall Survival Among Responders to Preoperative Chemoradiation for Locally Advanced Rectal Cancer (2001) (280)
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy (2007) (270)
Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer (2003) (265)
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. (2019) (265)
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. (2011) (263)
Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement (2009) (259)
Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. (2001) (243)
Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. (2016) (239)
Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. (2019) (235)
Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. (1998) (235)
Venous thrombosis in cancer patients: insights from the FRONTLINE survey. (2003) (218)
Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. (2001) (214)
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? (2001) (213)
A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) (2005) (212)
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. (2006) (207)
Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma (2012) (204)
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. (2009) (203)
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors (2012) (198)
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma (2004) (195)
Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. (2017) (193)
NCCN Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019: Featured Updates to the NCCN Guidelines (2019) (191)
Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. (2002) (190)
Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. (2014) (190)
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. (2010) (189)
Response to preoperative chemoradiation increases the use of sphincter‐preserving surgery in patients with locally advanced low rectal carcinoma (2003) (185)
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. (2010) (180)
HER2/neu-directed therapy for biliary tract cancer (2015) (176)
Association between hepatitis B virus and pancreatic cancer. (2008) (174)
Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival (2013) (174)
Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes (2015) (164)
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. (2011) (160)
Clinical and Pathologic Predictors of Locoregional Recurrence, Distant Metastasis, and Overall Survival in Patients Treated With Chemoradiation and Mesorectal Excision for Rectal Cancer (2006) (159)
Management of bevacizumab-associated bowel perforation: a case series and review of the literature. (2008) (157)
Transport properties of pancreatic cancer describe gemcitabine delivery and response. (2014) (156)
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies (2010) (155)
Perineural and Intraneural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma (2012) (146)
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. (2014) (144)
Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients (2018) (144)
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer (2008) (140)
Intraductal Papillary Mucinous Neoplasms of the Pancreas: Effect of Invasion and Pancreatic Margin Status on Recurrence and Survival (2006) (135)
Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation (2010) (132)
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. (2001) (129)
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. (2009) (127)
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. (2006) (126)
Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience (2016) (122)
Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu (2004) (120)
Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? (2007) (118)
Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. (2005) (116)
Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine (2009) (114)
Chemotherapy with 5‐fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma (2008) (113)
Preoperative Chemoradiation for Patients With Locally Advanced Adenocarcinoma of the Pancreas (1999) (113)
A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease (2012) (113)
Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. (2006) (111)
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. (2014) (108)
Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin (2010) (104)
Small cell carcinoma of the esophagus (2000) (103)
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. (2011) (100)
Thirty years' experience with Gamma Knife surgery for metastases to the brain. (2009) (100)
Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer (2011) (96)
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. (2021) (95)
The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal (2014) (93)
Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. (2009) (93)
Use of EUS-FNA in diagnosing pancreatic neoplasm without a definitive mass on CT. (2013) (91)
Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer (2015) (89)
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. (2006) (88)
Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. (2015) (87)
Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. (2006) (86)
Prognostic value of lymph node evaluation in small bowel adenocarcinoma (2010) (83)
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing (2014) (82)
Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine (2010) (82)
Combined EUS with FNA and ERCP for the evaluation of patients with obstructive jaundice from presumed pancreatic malignancy. (2008) (80)
Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. (2012) (80)
Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. (2006) (80)
Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy (2012) (80)
Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. (2002) (79)
Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival (2016) (78)
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. (2000) (77)
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation (2006) (77)
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. (2020) (77)
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors (2008) (77)
XRCC2 and XRCC3 Gene Polymorphismand Risk of Pancreatic Cancer (2008) (75)
Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? (2017) (74)
Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. (2008) (73)
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma (2017) (72)
Neoplasms of the Exocrine Pancreas (2003) (72)
Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer (2001) (72)
Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head (2001) (70)
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer (2017) (69)
Open Pancreaticoduodenectomy Case Volume Predicts Outcome of Laparoscopic Approach: A Population-based Analysis (2016) (69)
Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid Tumors (2008) (69)
Selective Reoperation for Locally Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma Following Primary Pancreatic Resection (2012) (68)
Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma (2017) (67)
5,10-Methylenetetrahydrofolate Reductase Polymorphisms and the Risk of Pancreatic Cancer (2005) (67)
A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study (2006) (66)
Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. (2012) (66)
The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma (2013) (64)
Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract (2005) (63)
Neoadjuvant therapy for resectable pancreatic cancer. (2004) (62)
Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. (2001) (61)
Pancreatic adenocarcinoma. (2010) (61)
T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment. (2001) (61)
Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future Progress (2008) (61)
Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma (2015) (60)
Incidence, Risk Factors, and Impact of Severe Neutropenia After Hyperthermic Intraperitoneal Mitomycin C (2009) (60)
A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma (2018) (60)
Chemoradiation for adenocarcinoma of the anus. (2003) (59)
Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy (2006) (59)
Retrospective analysis of dual-phase MDCT and follow-up EUS/EUS-FNA in the diagnosis of pancreatic cancer (2007) (58)
Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. (2008) (58)
Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. (2001) (58)
Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. (2019) (57)
Borderline resectable pancreatic cancer (2005) (57)
Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: A retrospective analysis. (2011) (56)
Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy (2017) (56)
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers (2005) (55)
Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis (2013) (55)
The MD Anderson Manual of Medical Oncology (2006) (54)
Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. (2007) (52)
Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy (2008) (52)
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. (2015) (52)
Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. (2016) (51)
Effects of base excision repair gene polymorphisms on pancreatic cancer survival (2007) (50)
Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. (2016) (49)
FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma (2017) (49)
Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma (2015) (49)
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer (2011) (48)
Phase II clinical trial of curcumin in patients with advanced pancreatic cancer. (2006) (47)
Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer (2015) (47)
Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single‐center, open‐label, phase 2 study (2017) (47)
Feasibility of an expressive‐disclosure group intervention for post‐treatment colorectal cancer patients (2011) (46)
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA (2019) (45)
Tumor Invasion of Muscular Vessels Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma Who Have Received Neoadjuvant Therapy and Pancreaticoduodenectomy (2012) (45)
Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. (2012) (44)
Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma (2016) (44)
The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. (2006) (42)
The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy (2016) (42)
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. (2022) (41)
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer (2015) (40)
Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. (1998) (40)
Morbidity and Mortality after Pancreaticoduodenectomy in Patients with Borderline Resectable Type C Clinical Classification (2013) (39)
Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. (2019) (39)
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer (2017) (39)
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy (2017) (39)
Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality (2016) (39)
The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy (2015) (39)
Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. (2021) (38)
Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. (2013) (38)
Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC. (2019) (38)
RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation. (2016) (37)
Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. (2019) (37)
Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma (2016) (36)
Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater (2017) (36)
Current Approaches and Future Strategies for Pancreatic Carcinoma (2000) (34)
A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. (2006) (34)
Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (2018) (34)
Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE (2013) (32)
Future chemoradiation strategies in pancreatic cancer. (2007) (32)
Imaging‐based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy (2018) (32)
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. (2000) (32)
Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. (2012) (32)
Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. (2018) (32)
Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. (2015) (31)
Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. (1998) (31)
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. (2016) (30)
Chemotherapy for Pancreatic Cancer: From Metastatic Disease to Adjuvant Therapy (2007) (30)
Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer (2014) (30)
A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. (2013) (30)
Pancreatic intraepithelial neoplasia and histological changes in non‐neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma (2013) (30)
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial (2022) (29)
Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms (2015) (29)
Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We? (2018) (29)
Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction (2015) (29)
Neoadjuvant strategies for pancreatic cancer. (2001) (29)
Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma (2019) (28)
Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial (2011) (28)
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma (2018) (28)
Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. (2012) (28)
Rate of bilirubin regression after stenting in malignant biliary obstruction for the initiation of chemotherapy (2008) (28)
Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. (2015) (28)
Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials (2013) (28)
Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater (2017) (27)
Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations (2013) (27)
Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial (2011) (27)
A High Positive Lymph Node Ratio is Associated with Distant Recurrence after Surgical Resection of Ampullary Carcinoma (2012) (27)
The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. (2016) (26)
Combined-modality treatment for operable pancreatic adenocarcinoma. (2005) (26)
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer (2013) (26)
Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. (2009) (25)
Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). (2006) (25)
NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA). (2016) (25)
Long‐term results of weekly/daily cisplatin‐based chemoradiation for locally advanced squamous cell carcinoma of the anal canal (2013) (25)
Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer (2019) (24)
A phase II trial of oxaliplatin plus capecitabine (xelox) as second line therapy for patients with advanced pancreatic cancer. (2006) (24)
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. (2020) (24)
Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer (2016) (24)
Clinical utility of circulating cell-free DNA in advanced colorectal cancer (2017) (23)
Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. (2010) (23)
Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma (2017) (23)
Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC (2017) (23)
A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma (2008) (22)
Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma (2014) (22)
A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients (2017) (21)
Dynamic changes during the treatment of pancreatic cancer (2018) (21)
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? (2014) (21)
Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. (2013) (20)
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma (2015) (20)
Are patients with cancer receiving adequate thromboprophylaxis? Results from FRONTLINE. (2003) (20)
Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET) (2007) (20)
Concurrent capecitabine and upper abdominal radiation therapy is well tolerated (2006) (20)
Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer (2021) (20)
Phase I trial of bevacizumab (BV) with concurrent radiotherapy (RT) and capecitabine (CAP) in locally advanced pancreatic adenocarcinoma (PA) (2005) (19)
Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results. (2021) (19)
Reirradiation to the abdomen for gastrointestinal malignancies (2009) (19)
Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). (2014) (19)
Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: A case‐control study (2008) (19)
Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience (2019) (18)
Curcumin and pancreatic cancer: Phase II clinical trial experience (2007) (17)
Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer. (2011) (17)
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients (2021) (17)
Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas: Great Logic, Grim Reality (2001) (17)
Origin and role of hepatic myofibroblasts in hepatocellular carcinoma (2020) (17)
Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. (2001) (17)
An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol (2019) (17)
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer (2005) (16)
Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. (2008) (16)
The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. (2013) (16)
Phase II trial of neoadjuvant bevacizumab (BEV), capecitabine (CAP), and radiotherapy (XRT) for locally advanced rectal cancer (2008) (16)
The integration of chemoradiation in the care of patient with localized pancreatic cancer. (2009) (16)
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial (2019) (16)
The Added Value of Multidisciplinary Care for Patients with Pancreatic Cancer (2008) (16)
Novel therapies for pancreatic cancer. (2001) (15)
A double‐blind, randomized, placebo‐controlled, phase 2 study of maintenance enzastaurin with 5‐fluorouracil/leucovorin plus bevacizumab after first‐line therapy for metastatic colorectal cancer (2012) (15)
A phase II trial of gemcitabine and celecoxib for metastatic pancreatic cancer (2005) (14)
Chemoprevention for pancreatic cancer (2003) (14)
Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases. (2008) (14)
Natural history and prognostic factors for localised small bowel adenocarcinoma (2020) (14)
Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. (2021) (14)
Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. (2016) (13)
Underreporting of Research Biopsies from Clinical Trials in Oncology (2017) (13)
Neoadjuvant therapy for resectable and borderline resectable adenocarcinoma of the pancreas. (2012) (13)
Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma (2018) (13)
A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases (2013) (13)
Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma (2017) (13)
Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy (2017) (13)
Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma (2016) (12)
Polymorphisms of genes involved in gemcitabine metabolism correlate with prognosis in patients receiving neoadjuvant therapy for pancreatic cancer (2008) (12)
Integration of a Mandatory Palliative Care Education Into Hematology-Oncology Fellowship Training in a Comprehensive Cancer Center: A Survey of Hematology Oncology Fellows. (2019) (12)
Exploiting molecular targets in pancreatic cancer. (2002) (12)
Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer (2019) (12)
Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (2007) (12)
Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer. (2015) (12)
Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies. (2009) (12)
Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study (2020) (12)
Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis (2016) (12)
Radiation Dose Considerations in the Palliative Treatment of Locally Advanced Adenocarcinoma of the Pancreas (2005) (12)
Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers (2020) (11)
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal (2017) (11)
Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?: A Pooled Analysis of Phase II Trials of Gemcitabine-Containing Doublets Plus Bevacizumab (2014) (11)
Multimodality management of localized pancreatic cancer. (2001) (11)
Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy? (2016) (10)
Preoperative gemcitabine (gem) and bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma (2008) (10)
A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs). (2017) (10)
Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer (2016) (10)
Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma (2019) (10)
Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery (2017) (10)
XRCC 2 and XRCC 3 Gene Polymorphism and Risk of Pancreatic Cancer (2008) (10)
Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. (2010) (10)
Retrospective analysis of dual-phase MDCT and follow-up EUS/EUS-FNA in the diagnosis of pancreatic cancer (2007) (10)
Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer (2006) (10)
Cross-sectional longitudinal study of the academic half-day format in a hematology-oncology fellowship training program (2015) (10)
NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience (2022) (10)
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis (2012) (10)
Phase II study of preoperation mFOLFIRINOX and chemoradiation for high-risk resectable and borderline resectable pancreatic adenocarcinoma. (2015) (9)
Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. (2008) (9)
Improving the AJCC/TNM staging for adenocarcinomas of the appendix: The prognostic impact of histologic grade. (2012) (9)
Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma (2015) (9)
Cisplatin (C) based chemoradiation (CXRT) for locally advanced squamous cell carcinoma (SCCA) of the anal canal (AC): A 20-year perspective. (2011) (9)
Neoadjuvant chemotherapy improves outcomes of chemoradiation therapy for locally advanced pancreatic cancer. (2006) (9)
The role of PET and PET-CT scanning in assessing response to neoadjuvant therapy in esophageal carcinoma. (2015) (8)
PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer (2022) (8)
Expression of Epithelial-Mesenchymal Transition Markers in Treated Pancreatic Ductal Adenocarcinoma. (2019) (8)
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) (2022) (8)
The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. (2014) (8)
Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients. (2014) (7)
First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (2018) (7)
The use of 5-fluorouracil and oxaliplatin (FOLFOX) for colorectal cancer is associated with the development of splenomegaly and thrombocytopenia (2008) (7)
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer (2013) (7)
Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy (2021) (7)
HepatoScore‐14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk (2020) (7)
Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma. (2018) (7)
Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. (2015) (7)
Multi-institutional Phase II Trial of Induction Cetuximab Gemcitabine and Oxaliplatin, followed by R (2010) (7)
Neoadjuvant Chemoradiation with Capecitabine Versus Infusional 5-fluorouracil (5-FU) for Locally Advanced Rectal Cancer: A Matched Pair Analysis (2005) (7)
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. (2013) (7)
Phase 1 clinical trials in 83 patients with pancreatic cancer (2011) (7)
Abstract 1449: ApoStream™, a new dielectrophoretic device for antibody-independent isolation and recovery of circulating tumor cells from blood of patients with metastatic pancreatic adenocarcinoma. (2013) (6)
A phase II study of ramucirumab for advanced, pre-treated biliary cancers. (2018) (6)
Evolution of Cancer Care in Response to the COVID‐19 Pandemic (2020) (6)
Tumor IGF-1 expression as a predictive biomarker for IGF1R-directed therapy in advanced pancreatic cancer (APC). (2012) (6)
A Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: RTOG PA0411 (2007) (6)
Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy (2006) (6)
Evaluating clinical and prognostic implications of Glypican 3 in hepatocellular carcinoma. (2016) (6)
Role of anticoagulation (AC) in patients with advanced pancreatic cancer (APC) with splanchnic venous thrombosis (SVT). (2011) (6)
Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses (2005) (6)
Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients (2020) (5)
The effect of antibiotic use on survival of patients with resected pancreatic ductal adenocarcinoma. (2019) (5)
Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy. (2021) (5)
Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma (2020) (5)
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. (2012) (5)
Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. (2020) (5)
Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma (2020) (5)
Treatment related toxicities with rapid-fractionation external beam radiation therapy and concomitant gemcitabine for locally advanced nonmetastic adenocarcinoma of the pancreas (1998) (5)
A retrospective analysis of antibiotics usage and effect on overall survival and progressive free survival in patients with metastatic pancreatic cancer. (2019) (5)
Abstract B121: Phase I study of MK‐0646, a humanized monoclonal antibody against IGF‐1R in combination with gemcitabine or gemcitabine + erlotinib (E) for advanced previously untreated pancreatic cancer (2009) (5)
Updated survival analysis of preoperative gemcitabine (gem) plus bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma. (2012) (5)
Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay (2015) (4)
Serum CA 19–9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC) (2008) (4)
Systemic chemotherapy in the setting of unresectable appendiceal epithelial neoplasms (AEN). (2012) (4)
Preoperative and postoperative chemoradiation for locally advanced rectal cancer: sphincter preservation and survival parameters in patients with pathological response to preoperative chemoradiation (2001) (4)
Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. (2020) (4)
RhuMab VEGF (bevacizumab) with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer: An active, well tolerated regimen (2004) (4)
A pooled analysis of phase II trials of gemcitabine (GEM)-containing doublets plus bevacizumab (BEV): Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer (APC)? (2012) (4)
Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater (2008) (4)
Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development (2022) (4)
A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. (2019) (4)
Prognostic significance of xCT gene single nucleotide polymorphisms (SNPs) in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (GEM) plus platinum analogues (PLAT). (2010) (4)
Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy (2009) (4)
Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer (2022) (4)
Does IGFR 1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer ? (2014) (4)
Use of gene expression analysis of periampullary carcinomas to identify biliary-like and intestinal-like subgroups of ampullary and duodenal carcinomas. (2011) (3)
Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib (2021) (3)
Early CgA Response as Predictor of Outcome Following Everolimus Therapy Among Patients With Low- to Intermediate- Grade Neuroendocrine Carcinoma: Analyses of a Single Institution Phase II Study (2010) (3)
A retrospective study of anti-EGFR antibody therapy in small bowel adenocarcinoma. (2018) (3)
Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma (2021) (3)
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients with Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase I Trial and Imaging-based Biomarker Validation. (2022) (3)
Impact of microsatellite instability (MSI) on tumor clonal evolution in metastatic colorectal cancer (mCRC). (2018) (3)
Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation (2015) (3)
Human genome meeting 2016 (2016) (3)
Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. (2007) (3)
2122 Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer (1999) (3)
Interim results of preoperative gemcitabine (gem) plus cisplatin followed by rapid fractionation chemoradiation for resectable pancreatic adenocarcinoma. (2006) (3)
5-FU-based adjuvant chemotherapy given after neoadjuvant chemoradiation and surgery for rectal cancer improves survival only among responders (2001) (3)
Reply: Cetuximab in small bowel adenocarcinoma: a new friend? (2010) (3)
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated by Gemcitabine-based Chemotherapy. (2022) (3)
Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma (2022) (3)
Preoperative (Neoadjuvant) Therapy for Resectable Adenocarcinoma of the Pancreas (2002) (3)
Loss of PTEN Expression Is Associated with Recurrence and Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma (2013) (3)
A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation. (2014) (3)
Treatment of localized, potentially resectable disease (2003) (3)
A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs): Updated survival analysis. (2018) (3)
A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer (2008) (3)
Background and H2O2-induced micronuclei in peripheral blood lymphocytes as a risk factor for pancreatic cancer (2004) (3)
Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer (2004) (3)
Abstract 164: PIK3CA mutation, aspirin use and mortality in patients with metastatic colorectal cancer participating in early-phase clinical trials . (2013) (3)
FOLFIRINOX in pancreatic cancer patients age 75 years or older. (2019) (3)
Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience (2022) (3)
Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. (2014) (3)
3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma (2022) (3)
Abstract CT131: NCI#9673 phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal: Immunologic correlates of response (2016) (2)
Hepatitis B- and C-associated hepatocellular carcinoma in a large U.S. cancer center: Do clinicopathologic features or patient outcomes differ by the potentially causative viruses? (2015) (2)
Adjuvant Therapy for Pancreatic Cancer: A Logical Strategy in Search of Progress (2011) (2)
Use of DPC-4 immunostaining of diagnostic cytology specimens to predict the pattern of tumor progression in locally advanced pancreatic cancer patients (LAPC). (2011) (2)
A phase II study of durvalumab (MEDI4736) (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). (2020) (2)
FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. (2020) (2)
Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRASG12D siRNA in patients with metastatic pancreatic cancer harboring a KRASG12D mutation. (2022) (2)
Characterization of germline genomic alterations in familial pancreas cancer. (2017) (2)
A double-blind, randomized, placebo-controlled, phase II study of maintenance enzastaurin with 5-FU/leucovorin plus bevacizumab following first-line therapy for metastatic colorectal cancer (mCRC). (2011) (2)
Pancreatic cancer: Is it time for Dr Whipple's orphans to have a Facebook page? (2012) (2)
Erratum: Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy (Abdominal Imaging (2006) 31 (568-574) DOI: 10.1007/s00261-005-0194-y) (2014) (2)
Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer. (2015) (2)
Neoplasms of the Ampulla of Vater (2003) (2)
A phase I trial of TAS-102 administered on a three times a day schedule in patients with solid tumors. (2006) (2)
709PA Phase II study of sorafenib and yttrium-90 glass microspheres for advanced hepatocellular carcinoma, BCLC stage C (2017) (2)
Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers. (2020) (2)
Pancreatic ductal adenocarcinoma: neoadjuvant therapies and pathology (2014) (2)
408 Preliminary biomarker and clinical ata of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer (2021) (2)
PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer (2022) (2)
Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. (2016) (2)
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma (2021) (2)
Association of elevated alpha-1 antitrypsin with advanced clinicopathologic features of hepatocellular carcinoma. (2017) (2)
The prognostic value of polymorphisms in the insulin-like growth factor receptor (IGFR) pathway in patients with locally advanced pancreatic cancer (LAPC). (2009) (2)
CEA as a blood-based biomarker in anal cancer (2021) (2)
BRAF mutation testing with a novel, rapid, fully automated molecular diagnostics prototype platform. (2013) (2)
Comparison of ampullary adenocarcinomas and duodenal adenocarcinomas with regard to clinical outcomes and responsiveness to fluoropyrimidine-based chemotherapy. (2011) (2)
Phase I trial of radiotherapy with concurrent bevacizumab, erlotinib, and capecitabine for locally advanced pancreatic cancer (LAPC). (2012) (2)
Diagnostic utility and prognostic performance of a 92-gene cancer classifier to molecularly profile periampullary adenocarcinomas (PAA). (2013) (2)
Effective management of treatment-related enteritis during preoperative chemoradiation for locally advanced rectal cancer (2000) (2)
Molecular classification of ampullary adenocarcinoma: Comparative prognostic performance of the 92-gene assay versus histomolecular analysis. (2014) (2)
Phase II study of panitumumab in KRAS wild-type metastatic adenocarcinoma of the small bowel or ampulla of vater. (2017) (2)
The protective effect of hormonal intake on risk of hepatocellular carcinoma in the United States. (2015) (1)
Novel Chemoradiation in Localized Pancreatic Cancer: Clinical Studies (2006) (1)
Impact of lymph node evaluation on survival for small bowel adenocaricnoma: Analysis of the Surveillance, Epidemiology and End Results (SEER) database. (2009) (1)
Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms. (2010) (1)
Abstract 1547: Expression of epithelial-to-mesenchymal transition markers (EMT) in treated pancreatic duct adenocarcinoma (2018) (1)
Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy (2023) (1)
O-0004 Updated Analysis of Phase II Study of the Anti-IGF-1R Antibody MK-0646 with Gemcitabine +/- Erlotinib for Advanced Pancreatic Cancer (APC) (2012) (1)
Oncology and public health (2012) (1)
The war on pancreatic cancer: are we gaining ground? (2010) (1)
Prognostic effect of angiotensin-converting-enzyme inhibitors (ACEI) and diuretics in patients with pancreatic cancer. (2016) (1)
Osteoclastic giant cell tumor of the pancreas: A distinct clinical and pathologic entity. (2010) (1)
Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688) (2019) (1)
Assessment of the impact of systemic chemotherapy (SC) on the quality of life (QOL) in patients with metastatic unresectable appendiceal epithelial neoplasms (AEN). (2013) (1)
Survival improvement for patients with metastatic colorectal cancer over twenty years (2023) (1)
Comprehensive analysis of potential predictive biomarkers for insulin-like growth factor type-1 receptor (IGF-1R) targeted therapy in pancreatic cancer. (2011) (1)
Utility of Neuropilin-1 in predicting survival in patients with hepatocellular carcinoma. (2018) (1)
Predictors of clonal evolution in metastatic colorectal cancer patients. (2015) (1)
Effect of dose-escalation of IMRT for unresectable pancreatic cancer 1 cm away from the luminal mucosa on long-term survival. (2015) (1)
Can we identify patients with cancer at high risk for cachexia? A prospective study in pancreatic cancer (PC). (2012) (1)
The natural history and role of surgical cytoreduction and systemic chemotherapy in high-grade mucinous adenocarcinomas of the appendix. (2013) (1)
Immune checkpoint blockade (ICB) response evaluation with MRI/MR elastography (MRE) in surgical and nonsurgical patients with HCC. (2020) (1)
Transforming growth factor (TGF) beta pathway and clinical outcome of pancreatic cancer. (2012) (1)
Plasma GH as a diagnostic and prognostic biomarker in HCC without cirrhosis. (2019) (1)
Association of human papillomavirus with unique clinicopathologic features in patients with metastatic squamous cell carcinoma of the anal canal. (2014) (1)
The role of partial splenic embolization (PSE) in the management of chemotherapy-induced thrombocytopenia. (2012) (1)
Erratum to: Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy (2011) (1)
Role of concurrent systemic chemotherapy and total parental nutrition (TPN) for the treatment of malignant small bowel obstruction (SBO). (2015) (1)
A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating cell-free tumor DNA (ctDNA) (TACT-D). (2020) (1)
Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. (2022) (1)
Abstract 48: Theranostic profiling of adolescents and young adults (AYA) with advanced fibrolamellar hepatocellular carcinoma identifies aberrant activation of the PI3K/AKT/MTOR signaling cascade. (2013) (1)
Authors Reply: How to manage febrile neutropenia during the COVID pandemic? In response to, "A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic". (2020) (1)
O-022A multi-institutional phase 2 study of single agent nivolumab in previously treated metastatic squamous cell carcinoma of the anal canal (SCCA) (2016) (1)
Relative value of serum cytokines and clinical factors in predicting weight loss in advanced pancreatic cancer (PC). (2011) (1)
735PThe prognostic significance of infiltrating lymphocytes in resectable pancreatic ductal adenocarcinoma in untreated versus neoadjuvant treated patients (2017) (1)
Association between the job types and the risk of hepatocellular carcinoma in the United States (2016) (1)
First line gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma. (2018) (1)
Is there a role for neoadjuvant chemotherapy in the management of non-carcinoid epithelial neoplasms of the appendix? (2007) (1)
RAS heterogeneity as a prognostic marker in metastatic colorectal cancer. (2017) (1)
GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. (2021) (1)
Abstract 2760: Phase I study of MK-0646, the humanized monoclonal antibody against IGF-1R in combination with gemcitabine or gemcitabine + erlotinib (E) for advanced, previously untreated pancreatic cancer (2010) (1)
Comprar The Md Anderson Manual Of Medical Oncology | Hagop Kantarian | 9780071701068 | MCGRAW HILL (2011) (1)
Abstract 891: FGF21 prevents high fat diet-induced pancreatic cancer in mice expressing oncogenic Kras (2015) (1)
Neoadjuvant therapy for adenocarcinomas of the duodenum and ampulla of Vater. (2011) (1)
CEA as a pharmacodynamic biomarker for metastatic anal cancer. (2018) (1)
Molecular profiling by circulating tumor DNA (ctDNA) and benefit from anti-PD-1 in HCC. (2019) (1)
Treatment of locally advanced disease (2003) (0)
Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. (2014) (0)
Abstracts reprinted from Journal of Clinical Oncology (2007) (0)
Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma (2016) (0)
Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. (2021) (0)
778 Morbidity and Mortality After Pancreaticoduodenectomy in Patients With Borderline Resectable Type C Clinical Classification (2013) (0)
The best level 1 evidence available (2008) (0)
Tumor interface stability on CT imaging is an early marker of response to cytotoxic therapy in pancreatic ductal adenocarcinoma. (2017) (0)
Hepatocellular Carcinoma Screening in High-Risk Populations in the United States (2016) (0)
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients (2022) (0)
Abstract 4491: Transforming growth factor (TGF) ≤ pathway and clinical outcome of pancreatic cancer (2012) (0)
A pilot study to assess the efficacy, safety, and pharmacodynamic effects of pembrolizumab and BL-8040 in patients with metastatic pancreatic cancer. (2018) (0)
Natural history of T1N0M0 hepatocellular carcinoma: Large scale study in the United States. (2015) (0)
IGF-1 Child-Turcotte-Pugh score as a predictor of overall survival to therapy in CTP-A, BCLC stage C patients with advanced hepatocellular carcinoma. (2020) (0)
Neoadjuvant Treatment of Pancreatic Cancer: Borderline-Resectable Disease (2009) (0)
Treatment outcome and prognostic indicators in 26 cases of fibrolamellar hepatocellular carcinoma under interferon based therapy. (2020) (0)
Title: Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA Short Title: Cell-free DNA in hepatocellular carcinoma Authors: (2019) (0)
218 A Randomized Phase II Study of Gemcitabine 1000mg/msq and Concurrent Radiotherapy Comparing Gemcitabine Alone for Unresectable Locally Advanced Pancreatic Adenocarcinoma (2010) (0)
Abstract CT204: High cytotoxic T-cell or polymorphonuclear cell infiltrates in the tumor microenvironment correlate with responses to BL8040 plus pembrolizumab combination therapy in metastatic pancreatic tumors: Scientific correlates of a phase II clinical trial (2020) (0)
Dose Escalation With an Intensity Modulated Radiation Therapy Technique in 15 to 28 Fractions Is Better Tolerated Than Are Standard Doses of 3DCRT for LAPC (2016) (0)
NCCN Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology (2010) (0)
Meat consumption and BRAF mutation status in colorectal cancer. (2019) (0)
Clinical Decision Making in Pancreatic Cancer (2010) (0)
Clinical and prognostic significance of serum levels of fatty acid binding proteins in hepatocellular carcinoma (HCC). (2019) (0)
Abstract 2599: Circulating nucleic acids as biomarkers of prognosis and chemorefractory status in metastatic pancreatic cancer (2018) (0)
Outcome analyses of patients with metastatic cervical cancers in a phase I clinic. (2013) (0)
(S022) Can Imaging-Based Biomarkers of Pancreatic Cancer be Used to Select Patients for Dose-Escalated Radiotherapy? (2017) (0)
Utility of Tumor Interface Stability as an Imaging Biomarker of Treatment Outcomes in Patients With Pancreatic Cancer Treated With Concurrent Bevacizumab and Radiation Therapy (2017) (0)
Current Understanding of Colorectal Neoplasia (2003) (0)
Next-generation sequencing (NGS) in patients with advanced metastatic breast cancer: Identification of molecular alterations and analysis of associations with treatment on phase I studies at MD Anderson Cancer Center. (2013) (0)
Staging and Therapeutic Approaches for Patients with Localized, Potentially Curable Pancreatic Adenocarcinoma (2005) (0)
PHASE II STUDY OF MTOR-INHIBITOR RAD001 AND ERLOTINIB FOR ADVANCED, GEMCITABINE-REFRACTORY PANCREATIC CANCER (2008) (0)
Abstract 5236: Prospective clinical application of circulating cell-free DNA sequencing in metastatic colorectal cancer (2015) (0)
Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential (2023) (0)
Single institutional experience of bevacizumab-based regimens in treatment of hepatocellular carcinoma. (2015) (0)
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience (2017) (0)
P-114A phase II trial of bevacizumab and erlotinib as second line therapy for advanced hepatocellular carcinoma (2015) (0)
Additional file 2: of Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma (2018) (0)
Study of genotypic variations and protein expression of the xCT subunit of cystine/glutamate transporter in pancreatic cancer. (2011) (0)
A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer. (2015) (0)
Cost-effectiveness of neoadjuvant (NeoAdj) versus adjuvant (Adj) therapies for resectable pancreatic cancer (PC). (2010) (0)
Neoadjuvant versus upfront surgical strategies in patients with resectable pancreatic adenocarcinoma: A decision analysis. (2010) (0)
Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. (2019) (0)
Human genome meeting 2016 (2016) (0)
Abstract 1178: Phase I clinical trial of Lenalidomide in combination with Sorafenib in patients with advanced cancer. (2013) (0)
924 How Successful Is Endoscopic Retrograde Cholangiopancreatography in Patients With Biliary Obstruction Post-Pancreaticoduodenectomy? (2019) (0)
The use of biologic therapy in the treatment of unresectable appendiceal neoplasms (2008) (0)
Global Protein Aberration Score (GloPAS): A comprehensive risk score to predict hepatocellular carcinoma biology and estimate patients’ survival. (2018) (0)
Prognostic and predictive effect of COX-2 expression in appendiceal adenocarcinomas. (2012) (0)
GIANT CELL CARCINOMA OF PANCREAS: MD ANDERSON EXPERIENCE (2008) (0)
A phase II study of capecitabine and oxaliplatin (CAPOX) in metastatic adenocarcinoma of the small bowel (SBA) or ampulla of Vater. (2006) (0)
Predictors for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). (2018) (0)
Oncologic and functional hazards of obesity among patients with locally advanced rectal cancer. (2011) (0)
International validation of an IGF-CTP scoring system for assessing hepatic reserve in hepatocellular carcinoma. (2015) (0)
Use of operability classifications to predict outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. (2012) (0)
Outcomes of patients ≥ 65 yrs with advanced cancer treated on phase I clinical trials. (2013) (0)
A double-blind, randomized placebo-controlled, phase II study of maintenance enzastaurin (ENZ) with 5-FU/leucovorin (LV) plus bevacizumab (BV) following first-line therapy for metastatic colorectal cancer (mCRC). (2011) (0)
HER2/neu-directed therapy for biliary tract cancer. (2015) (0)
Retrospective analysis of taxane-based therapy in advanced small bowel adenocarcinoma (SBA). (2018) (0)
Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center. (2015) (0)
Abstract 2771: Clinical outcomes and prognostic factors in 83 patients with pancreatic cancer treated in phase I clinical trials at M.D. Anderson Cancer Center (2010) (0)
Management of solid and cystic lesions of the pancreas (2016) (0)
Pattern of recurrence after curative resection of stage I-III duodenal adenocarcinoma. (2020) (0)
Radiation Therapy for High-Grade Neuroendocrine Carcinoma of the Rectum and Anal Canal (2014) (0)
Abstract B36: Maintenance chemotherapy after chemoradiation in patients with locally advanced pancreatic cancer (2019) (0)
Current controversies in the management of pancreatic cancer. (2006) (0)
When Does Personalized Cancer Therapy Research Provide Positive Return on Investment in Europe (2012) (0)
13 Targeted Drug Therapy in Pancreatic Cancer (0)
Creation and implementation of a chief fellow of quality improvement in an oncology fellowship program. (2018) (0)
Pancreatic AdenocarcinomaPractice Guidelines in Oncology (2010) (0)
Baseline level and early on-treatment clearance of circulating mutant KRAS in metastatic pancreatic ductal adenocarcinoma treated with chemotherapy with or without immunotherapy. (2021) (0)
Role of biologic therapy in the treatment of unresectable appendiceal epithelial neoplasms (AEN). (2012) (0)
Mo1503 – Comparison of Self-Expanding Metal Stents in Malignant Biliary Obstruction: Then and Now – a Tertiary Cancer Center Experience (2019) (0)
Effects of a Pragmatic Home-based Exercise Program Concurrent with Neoadjuvant Therapy on Physical Function of Patients with Pancreatic Cancer: The Pancfit Randomized Clinical Trial. (2023) (0)
Neoadjuvant Treatment of Pancreatic Cancer (2018) (0)
Targeted Drug Therapy in Pancreatic Cancer (2008) (0)
Abstract 1209: Next generation sequencing demonstrates multiple gene amplifications and mutations in 3 patients with estrogen receptor-positive breast cancer with responses to treatment with combination aromatase and PI3K/AKT/mTOR pathway inhibition. (2013) (0)
The Czito et al article reviewed (2000) (0)
Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer (2022) (0)
Survival benefit to immunotherapy according to site of organ involvement in metastatic anal cancer. (2023) (0)
Characteristics and survival of patients with advanced cancer and TP53 mutations in phase I clinical trials. (2013) (0)
Retrospective review of patients with adenocarcinoma of the pancreas and ovarian metastasis: Clinical characteristics, treatment strategies, and survival data. (2006) (0)
IGF-Child-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy. (2019) (0)
343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer (2021) (0)
Impact of multidisciplinary therapy on high-grade appendiceal adenocarcinoma (AA). (2013) (0)
Rate of Birubin Regression Post-Biliary Stenting in Malignant Biliary Obstruction for Initiation of Chemotherapy: How Soon Should We Repeat ERCP? (2006) (0)
Clinical outcomes and prognostic factors of hepatic arterial infusion (HAI) chemotherapy combination regimens in 202 patients with advanced cancer metastatic to the liver: The phase I program M. D. Anderson Cancer Center experience. (2010) (0)
The protective effect of physical activity on risk of hepatocellular carcinoma in USA. (2016) (0)
980 Preliminary results of a phase I study of rhumab VEGF (bevacizumab) with concurrent radiotherapy (XRT) and capecitabine (CAP) in locally advanced pancreatic cancer (2003) (0)
IGF-Child-Turcotte-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy. (2019) (0)
Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery (2016) (0)
The association between female hormonal supplementation and molecular types in colorectal cancer. (2019) (0)
Comparison of patterns of failure between T3 and T4 rectal cancer after preoperative chemoradiation (2000) (0)
Abstract B028: Changes in exosomal RNA expression associate with treatment response to BRAF + EGFR + PD-1 blockade in MSS, BRAFV600E colorectal cancer: A liquid biopsy approach (2022) (0)
Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with (2015) (0)
1076 : Does the Addition of Bevacizumab to Chemoradiation Prolong Median Survival In Locally Advanced Pancreatic Cancer Patients? (2006) (0)
Incidence of mucositis in patients treated with mTOR inhibitor-based regimens and correlation to treatment response. (2013) (0)
Prognostic significance of periostin in patients with hepatocellular carcinoma. (2018) (0)
RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. (2022) (0)
Is CA19-9 Response Following Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer an Early Surrogate for Eventual Survival Outcomes? (2013) (0)
Abstract 4742:APCWT/RASWT/BRAFWTtumors represent an under recognized poor prognostic group of right sided colorectal cancer (2017) (0)
Phase II study of bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater. (2016) (0)
The war on pancreatic cancer: we are not there yet. (2014) (0)
Treatment of metastatic disease (2003) (0)
Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts). (2016) (0)
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma (2021) (0)
FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis. (2019) (0)
P-261 Phase I study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma (2021) (0)
A retrospective single institution review of 90 pancreatic adenosquamous cancer (PASC) patients (pts). (2015) (0)
Attitudes and beliefs of a mandatory palliative care rotation by hematology and medical oncology fellows at a major comprehensive cancer center. (2018) (0)
1067 : Predictors of Tumor Response and Downstaging in Patients Treated with Preoperative Chemoradiation for Rectal Cancer (2006) (0)
Abstract B35: Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging (2019) (0)
328 POSTER Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer (2008) (0)
Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. (2020) (0)
[Frontiers in Bioscience 3, e194-204, November 1, 1998] 194 NEOADJUVANT CHEMORADIATION FOR ADENOCARCINOMA OF THE PANCREAS (1998) (0)
The role of ALBI and IGF-CTP score in refining prognostication of HCC. (2020) (0)
Abstract A023: Influence of pre-diagnosis obesity and post-diagnosis aspirin use on survival from stage IV colorectal cancer (2022) (0)
A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance). (2018) (0)
Clinical decision-making in pancreaticcancer (2018) (0)
A prospective biomarker study to assess IGF-1 score ability to sub-stratify Child-Turcotte-Pugh classes and predict response to systemic therapy in hepatocellular carcinoma. (2017) (0)
Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients. (2015) (0)
Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. (2008) (0)
The war on pancreatic cancer (2014) (0)
A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer (2008) (0)
Female sex and standardized mitomycin-c dose are associated with increased risk of neutropenia after hyperthermic intraperitoneal chemotherapy (2007) (0)
Tu1402 COMPARISON OF THE PERFORMANCE OF COVERED METAL STENTS AND UNCOVERED METAL STENTS IN THE MANAGEMENT OF MALIGNANT BILIARY STRICTURES (MBO) IN 1012 PATIENTS. (2018) (0)
Effect of Radiotherapy (RT) on Outcomes in Patients (Pts) With Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BRPC, LAPC). (2021) (0)
In Reply (2020) (0)
IGF-Child-Pugh score as a predictor of treatment outcome in advanced hepatocellular carcinoma patients treated with sorafenib. (2019) (0)
418 Evolution of Outcomes of Patients With Pancreatic Ductal Adenocarcinoma Undergoing Pancreatoduodenectomy Following Preoperative Therapy (2016) (0)
The prognostic signi fi cance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials (2013) (0)
Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC). (2023) (0)
Phase I study of interleukin-4 (rHuIL-4) combined with chemotherapy in gastrointestinal (GI) malignancies (1997) (0)
Abstract No. 189: Partial Splenic Embolization for Cancer Patients with Thrombocytopenia Requiring Systemic Chemotherapy (2008) (0)
Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials. (2023) (0)
Cytotoxic Chemotherapy for Pancreatic Cancer: Past, Present, and Future (2002) (0)
Systematic survey of therapeutic trials for metastatic colorectal cancer. (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert A. Wolff?

Robert A. Wolff is affiliated with the following schools:

University of Alabama
MD Anderson Cancer Center
Fudan University

Robert A. Wolff's Academic­Influence.com Rankings

Why Is Robert A. Wolff Influential?

Robert A. Wolff's Published Works

Published Works

What Schools Are Affiliated With Robert A. Wolff?

Robert A. Wolff's AcademicInfluence.com Rankings